1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. News
  7. Summary
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
3.920 USD   -9.26%
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Dynamic Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CorMedix to Participate in Upcoming January Conferences

01/04/2022 | 08:02am EDT

BERKELEY HEIGHTS, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will be participating in several upcoming investor conferences in January.

Investor Conference Details

LifeSci Partners – 11th Annual Corporate Access Event
        Wednesday, January 5thFriday, January 7th
        To register and submit one-on-one meeting requests, Click Here

H.C. Wainwright Bioconnect Virtual Conference
        Monday, January 10thThursday, January 13th
        To register for the conference, Click Here

Biotech Showcase Virtual Conference
        Monday, January 10thWednesday, January 12th
        To register and submit one-on-one meeting requests, Click Here

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the NDA received priority review in recognition of its potential to address an unmet medical need. QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed. The Company received a Complete Response Letter from FDA stating that the NDA could not be approved until satisfactory resolution of deficiencies at the contract manufacturing facility, including in-process controls for the filling operation. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
(617) 430-7576


Primary Logo

Source: CorMedix, Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about CORMEDIX INC.
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Dynamic Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell Small Cap Comp Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000E Index
CI
More news
Analyst Recommendations on CORMEDIX INC.
More recommendations
Financials (USD)
Sales 2022 0,64 M - -
Net income 2022 -36,5 M - -
Net cash 2022 118 M - -
P/E ratio 2022 -4,97x
Yield 2022 -
Capitalization 169 M 169 M -
EV / Sales 2022 80,7x
EV / Sales 2023 3,68x
Nbr of Employees 30
Free-Float 98,7%
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,32 $
Average target price 22,00 $
Spread / Average Target 409%
EPS Revisions
Managers and Directors
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CORMEDIX INC.-5.05%169
MERCK KGAA-26.06%74 764
KYOWA KIRIN CO. LTD.-0.64%12 330
SK BIOPHARMACEUTICALS CO., LTD.-19.75%4 650
BETTA PHARMACEUTICALS CO., LTD.-27.13%3 596
YUHAN CORPORATION-7.09%2 987